Lexian Tong

Zhejiang Province Key Laboratory Of Anti Cancer Drug Research
Hangzhou, 310058, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Discovery of Novel Trisubstituted Pyridine Derivatives as EED-H3K27me3 Inhibitors for the Treatment of Multiple Sclerosis.

Discovery of Novel Trisubstituted Pyridine Derivatives as EED-H3K27me3 Inhibitors for the Treatment of Multiple Sclerosis.

Journal: Journal of medicinal chemistry

Published: March 18, 2026

Inhibition of EED-mediated histone methylation alleviates neuroinflammation by suppressing WNT-mediated dendritic cell migration.

Inhibition of EED-mediated histone methylation alleviates neuroinflammation by suppressing WNT-mediated dendritic cell migration.

Journal: Journal of neuroinflammation

Published: October 17, 2024

Design, synthesis, and antitumor activity evaluation of potent fourth-generation EGFR inhibitors for treatment of Osimertinib resistant non-small cell lung cancer (NSCLC).

Design, synthesis, and antitumor activity evaluation of potent fourth-generation EGFR inhibitors for treatment of Osimertinib resistant non-small cell lung cancer (NSCLC).

Journal: Bioorganic chemistry

Published: March 20, 2024

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: September 18, 2023

Discovery of 2-Aminopyrimidine Derivatives as Potent Dual FLT3/CHK1 Inhibitors with Significantly Reduced hERG Inhibitory Activities.

Discovery of 2-Aminopyrimidine Derivatives as Potent Dual FLT3/CHK1 Inhibitors with Significantly Reduced hERG Inhibitory Activities.

Journal: Journal of medicinal chemistry

Published: August 16, 2023

Dual inhibition of CHK1/FLT3 enhances cytotoxicity and overcomes adaptive and acquired resistance in FLT3-ITD acute myeloid leukemia.

Dual inhibition of CHK1/FLT3 enhances cytotoxicity and overcomes adaptive and acquired resistance in FLT3-ITD acute myeloid leukemia.

Journal: Leukemia

Published: November 16, 2022

Discovery of new macrophage M2 polarization modulators as multiple sclerosis treatment agents that enable the inflammation microenvironment remodeling.

Discovery of new macrophage M2 polarization modulators as multiple sclerosis treatment agents that enable the inflammation microenvironment remodeling.

Journal: European journal of medicinal chemistry

Published: May 31, 2022

Identification of 2-Aminopyrimidine Derivatives as FLT3 Kinase Inhibitors with High Selectivity over c-KIT.

Identification of 2-Aminopyrimidine Derivatives as FLT3 Kinase Inhibitors with High Selectivity over c-KIT.

Journal: Journal of medicinal chemistry

Published: February 09, 2022

Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells.

Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells.

Journal: European journal of medicinal chemistry

Published: January 11, 2022

Recent advances in FLT3 inhibitors for acute myeloid leukemia.

Recent advances in FLT3 inhibitors for acute myeloid leukemia.

Journal: Future medicinal chemistry

Published: April 22, 2020

Discovery of (R)-5-((5-(1-methyl-1H-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a novel CHK1 inhibitor for hematologic malignancies.

Discovery of (R)-5-((5-(1-methyl-1H-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a novel CHK1 inhibitor for hematologic malignancies.

Journal: European journal of medicinal chemistry

Published: March 02, 2019

Showing 1-11 of 11

Last Updated: 09/26/2026